About Base Genomics
Base Genomics is a company based in Oxford (United Kingdom) founded in 2019 by Chunxiao Song, Oliver Waterhouse, and Yibin Liu was acquired by Exact Sciences in October 2020. Base Genomics has raised $11 million across 1 funding round from investors including Exact Sciences and Oxford Science Enterprises. The company has 19 employees as of December 31, 2021. Base Genomics operates in a competitive market with competitors including Denali Therapeutics, MiRagen, Poseida Therapeutics, Castle Biosciences and Personalis, among others.
- Headquarter Oxford, United Kingdom
- Employees 19 as on 31 Dec, 2021
- Founders Chunxiao Song, Oliver Waterhouse, Yibin Liu
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Exact Sciences Innovation, Ltd
- Date of Incorporation 17 Jul, 2019
- Jurisdiction LONDON, ENGLAND
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$11 M (USD)
in 1 rounds
-
Latest Funding Round
$11 M (USD), Seed
Jun 03, 2020
-
Investors
Exact Sciences
& 1 more
-
Employee Count
19
as on Dec 31, 2021
-
Acquired by
Exact Sciences
(Oct 27, 2020)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Base Genomics
Base Genomics has successfully raised a total of $11M through 1 strategic funding round. The most recent funding activity was a Seed round of $11 million completed in June 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Base Genomics
Base Genomics has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include Exact Sciences and Oxford Science Enterprises.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investment management services for science ventures are provided in Oxford.
|
Locked | Locked | Locked | |
|
Non-invasive molecular diagnostic tests for cancer detection are provided.
|
Locked | Locked | Locked |
Investor details for Base Genomics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Base Genomics
Investment portfolio details for Base Genomics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Base Genomics
Detailed financials for Base Genomics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Base Genomics Comparisons
Peer comparison for Base Genomics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Base Genomics
Base Genomics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Denali Therapeutics, MiRagen, Poseida Therapeutics, Castle Biosciences and Personalis, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| Locked | Locked | Locked |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| Locked | Locked | Locked |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| Locked | Locked | Locked |
Precision diagnostic and prognostic tests are developed by Castle Biosciences.
|
|
| Locked | Locked | Locked |
Genomic sequencing and diagnosis software is provided for healthcare.
|
|
| Locked | Locked | Locked |
Therapeutics for aging diseases are developed by targeting senescent cells.
|
Detailed competitors of Base Genomics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Base Genomics
Complete news archive for Base Genomics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Base Genomics
Base Genomics was founded in 2019 and raised its 1st funding round 1 year after it was founded.
Base Genomics is headquartered in Oxford, United Kingdom. It is registered at Oxford, Oxfordshire, United Kingdom.
Oliver Waterhouse is the current CEO of Base Genomics. They have also founded this company.
Base Genomics is a funded company, having raised a total of $11M across 1 funding round to date.
As of Dec 31, 2021, the latest employee count at Base Genomics is 19.
Base Genomics was founded in 2019 in Oxford, United Kingdom, and operates in the biotechnology sector focused on epigenetics. TET-assisted pyridine borane sequencing (TAPS) technology is provided for DNA methylation analysis via bisulfite sequencing, enabling early cancer detection and personalized medicine from samples. Additional services include non-invasive prenatal testing, single-cell sequencing, and biomarker discovery.
Base Genomics's top competitors include Personalis, Poseida Therapeutics and Denali Therapeutics.
Base Genomics has 2 investors. Key investors include Exact Sciences, and Oxford Science Enterprises.